ICD-10 guidance calls for dual coding during transition

A final rule regarding the new ICD-10 implementation date is coming from the Centers for Medicare & Medicaid Services but new guidance indicates the need for dual coding.

The agency's guidance offers details on the need for dual coding and processing of ICD-9 and ICD-10 claims during the transition. "Dual coding and dual processing can be useful tools to prepare for ICD-10 by testing whether you are able to prepare, send, receive and process transactions with ICD-10. However, ICD-10 can be used for testing purposes only before the compliance date; providers and payers cannot use ICD-10 in 'live' transactions for dates of service before the ICD-10 compliance date," according to the guidance.

The guidance says providers and payers will be expected to use ICD-9 in tranactions for services provided before the compliance date and ICD-10 in transactions for services provided on or after the compliance date. "While providers and payers must be able to use both ICD-9 and ICD-10 codes after the compliance date to accommoate backlogs in claims and other transactions, they will not be able to choose to use either ICD-9 or ICD-10 for a given transaction. The date of service determines whether ICD-9 or ICD-10 is to be used."

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.